Melanoma Treatment Options: A Complete Guide

The treatment of melanoma has changed more dramatically over the past 15 years than during any comparable period in the history of cancer therapy. What was once a uniformly devastating diagnosis at advanced stages has been transformed by the introduction of immunotherapy and targeted therapy. Patients who would have had limited treatment options and poor outcomes a decade ago now face a fundamentally different landscape, with multiple effective treatment approaches and substantially improved survival.

For early-stage melanoma, surgical removal often provides definitive treatment with excellent outcomes. For more advanced disease, the combination of surgery with adjuvant systemic therapy substantially reduces recurrence rates. For metastatic disease, modern systemic therapies have produced unprecedented response rates and durable responses for many patients.

This article explains the spectrum of melanoma treatment options, when each is used, what patients can expect from each approach, and how treatment decisions are made.

For more on melanoma broadly, see Melanoma: Early Detection Saves Lives — The "Ugly Duckling" Sign Explained.

How Treatment Decisions Are Made

Treatment decisions in melanoma involve several specific considerations.

Stage at diagnosis is the most important factor. The TNM staging system classifies melanoma based on the primary tumor (T), regional lymph node involvement (N), and distant metastases (M), producing stages from 0 through 4.

Tumor characteristics beyond stage also matter. Breslow thickness affects surgical margins and sentinel lymph node biopsy decisions. Ulceration is associated with worse prognosis and may influence treatment intensity. Mitotic rate provides additional prognostic information.

Genetic and molecular characteristics increasingly guide treatment selection. Approximately half of melanomas carry BRAF mutations, which can be targeted with specific therapies. Other mutations including NRAS and KIT can also influence options.

Patient factors including age, overall health, and personal preferences shape the approach.

For more on staging and prognosis, see Melanoma Survival Rates by Stage: What the Numbers Really Mean.

Surgery

Wide Local Excision

For most melanomas, wide local excision is the primary surgical treatment. The procedure removes the melanoma along with a margin of surrounding healthy skin.

Margin width depends on tumor thickness:

• Melanoma in situ (Stage 0): 5 mm margins
• Thin invasive melanomas (<1 mm): 1 cm margins
• Thicker melanomas: 1–2 cm margins

The procedure is typically performed under local anesthesia for smaller lesions. Recovery is generally straightforward, with various reconstructive techniques available for larger defects.

Sentinel Lymph Node Biopsy

For melanomas thicker than 0.8 mm, particularly those with ulceration, sentinel lymph node biopsy is often recommended. The procedure identifies the first lymph nodes draining the melanoma site and assesses whether cancer has spread.

If cancer is found in the sentinel nodes, staging changes to Stage 3, with implications for further treatment. Current evidence suggests that complete lymph node dissection is not routinely required when sentinel nodes are positive, with effective adjuvant therapy often preferred.

Lymph Node Dissection

For patients with clinically apparent lymph node involvement, lymph node dissection removes all nodes in the affected area. Side effects can include lymphedema of the affected limb.

Immunotherapy

Immunotherapy has transformed the treatment of advanced melanoma by enhancing the body's immune response against cancer.

Checkpoint Inhibitors

PD-1 inhibitors (pembrolizumab, nivolumab) target the PD-1 protein on immune cells and produce response rates of approximately 40–45% in advanced melanoma. A substantial proportion of responders have durable responses persisting for years.

CTLA-4 inhibitors (ipilimumab) target a different immune checkpoint. Response rates as monotherapy are somewhat lower, but the drug contributes substantially when combined with PD-1 inhibitors.

LAG-3 inhibitors (relatlimab) represent a newer class. The combination of nivolumab plus relatlimab produces higher response rates than nivolumab alone with a somewhat different toxicity profile.

Combination Immunotherapy

The combination of nivolumab and ipilimumab produces response rates of approximately 60% in advanced melanoma, higher than either drug alone, but with more immune-related side effects. For patients who can tolerate the increased toxicity, the higher response rate may be preferred.

Adjuvant Immunotherapy

For Stage 3 melanoma after surgical removal, adjuvant immunotherapy reduces recurrence rates by approximately 30–50% compared to observation. Pembrolizumab and nivolumab have both demonstrated benefit. Adjuvant use has expanded to selected higher-risk Stage 2 patients.

Side Effects of Immunotherapy

Immune-related adverse events can affect multiple organ systems, including the skin, gastrointestinal tract, lungs, liver, and endocrine glands. Management typically involves corticosteroids and, in severe cases, additional immunosuppressive medications. With appropriate monitoring, most patients can complete planned therapy.

Targeted Therapy

For melanomas with specific genetic mutations, targeted therapy provides another effective treatment approach.

BRAF and MEK Inhibitor Combinations

Approximately half of melanomas carry BRAF mutations. BRAF inhibitors block the abnormal BRAF protein; MEK inhibitors block a related protein in the same pathway. Combination therapy produces higher response rates than BRAF inhibition alone.

Widely used combinations include:

• Dabrafenib plus trametinib
• Vemurafenib plus cobimetinib
• Encorafenib plus binimetinib

Response rates with combination targeted therapy are approximately 60–70% in BRAF-mutant melanoma.

Comparison With Immunotherapy

Targeted therapy typically produces faster responses than immunotherapy, but durability is generally shorter, with many patients eventually developing resistance. The choice between targeted therapy and immunotherapy as first-line depends on disease aggressiveness, patient preferences, and tolerability.

Side Effects of Targeted Therapy

Common side effects include fevers, fatigue, gastrointestinal symptoms, and skin changes. The BRAF plus MEK combination produces fewer secondary skin cancers than BRAF inhibitor alone.

Adjuvant and Neoadjuvant Therapy

Adjuvant Therapy

For Stage 3 melanoma, adjuvant therapy after surgical removal has become standard of care. Options include:

• Pembrolizumab or nivolumab (for all Stage 3 patients)
• Dabrafenib plus trametinib (for BRAF-mutant Stage 3 patients)

Duration is typically one year. The decision involves weighing recurrence risk reduction against potential side effects.

Neoadjuvant Therapy

The use of immunotherapy before surgery for Stage 3 melanoma is an emerging approach showing excellent results. Short courses of immunotherapy before surgery have demonstrated substantial improvements in outcomes compared to surgery alone or adjuvant therapy alone.

Treatment by Stage

Stage 0: Surgical excision with 5 mm margins. Generally curative; no additional treatment required.

Stage 1: Wide local excision with 1 cm margins. Sentinel node biopsy for thicker lesions. Systemic therapy typically not required.

Stage 2: Wide local excision with 1–2 cm margins. Sentinel node biopsy recommended. Adjuvant therapy increasingly considered for Stage 2B and 2C.

Stage 3: Surgical removal plus management of involved nodes, followed by adjuvant systemic therapy. Neoadjuvant immunotherapy is an emerging option for selected patients.

Stage 4: Systemic therapy is the cornerstone. Surgery and radiation may be used for symptomatic metastases or oligometastatic disease.

Radiation Therapy

Radiation has specific roles in melanoma treatment:

• Brain metastases: Stereotactic radiosurgery delivers focused high-dose radiation to specific targets with minimal effects on surrounding tissue. Whole-brain radiation may be used for multiple lesions.
• Symptomatic metastases: Radiation can relieve pain and bleeding at other sites.
• Unresectable or recurrent disease: Radiation may be used as primary or adjuvant treatment in specific situations.

Treatment of Metastatic Disease

First-Line Treatment

For BRAF wild-type melanoma, immunotherapy (single-agent PD-1 inhibition or combination) is typically the first-line approach.

For BRAF-mutant melanoma, the choice between immunotherapy and targeted therapy as first-line depends on individual considerations. Both approaches are effective, and optimal sequencing continues to be studied.

Subsequent Lines of Therapy

For patients whose disease progresses, options include switching immunotherapy combinations, transitioning to targeted therapy (or vice versa), or participating in clinical trials of newer agents.

Special Situations

Combination immunotherapy has shown effectiveness for brain metastases. For oligometastatic disease, surgical removal or radiation combined with systemic therapy may provide more comprehensive treatment.

Clinical Trials

Clinical trials provide access to investigational treatments and continue to drive advances in melanoma therapy. Many current standard treatments were available only through trials a few years ago. For patients with advanced melanoma, particularly after progression on standard treatments, discussing clinical trial options with the treating oncologist is appropriate.

Multidisciplinary Care

Comprehensive melanoma care involves a multidisciplinary team:

• Dermatologists manage initial diagnosis and ongoing surveillance
• Surgical oncologists perform wide local excision, sentinel node biopsy, and lymph node dissection
• Medical oncologists manage immunotherapy and targeted therapy
• Radiation oncologists are involved when radiation is indicated
• Pathologists provide accurate diagnosis and tumor characterization that guides treatment decisions

Coordination through multidisciplinary tumor boards supports comprehensive care.

Surveillance and Follow-Up

After treatment, surveillance for recurrence and new primary melanomas is an important part of long-term care. The frequency depends on original stage — from periodic skin examinations for early-stage patients to more intensive imaging-based surveillance for higher-stage disease.

Risk of recurrence is highest in the first few years and declines progressively. Risk of new primary melanomas is elevated throughout life, making ongoing skin surveillance important.

For more on evaluation, see How Is Melanoma Diagnosed? Skin Examination, Dermoscopy, and Biopsy.

Living With and After Treatment

Beyond medical treatment, several considerations affect the experience of living with melanoma:

• Physical recovery from surgery progresses over weeks, depending on size and location
• Side effect management during systemic therapy requires attention; most patients can complete planned therapy with appropriate support
• Emotional and psychological effects deserve attention; many patients benefit from counseling or support groups
• Sun protection becomes a lifelong priority, including broad-spectrum sunscreen, protective clothing, and avoidance of tanning beds
• Long-term surveillance continues for many years through regular skin examinations and any indicated imaging

Conclusion

The treatment of melanoma has been transformed by advances in immunotherapy and targeted therapy. For early-stage disease, surgery often provides definitive treatment. For advanced disease, modern systemic therapies have produced unprecedented response rates and durable responses for many patients.

Treatment decisions depend on stage, tumor characteristics, genetic mutations, and individual factors. Multidisciplinary care coordinates the expertise of dermatologists, surgeons, medical oncologists, and radiation oncologists to provide comprehensive treatment.

For patients newly diagnosed, the practical message is encouraging: available treatments have improved substantially, outcomes continue to improve with modern care, and the combination of accurate staging, individualized planning, and experienced specialist involvement supports the best possible outcomes.

For more on melanoma broadly, see Melanoma: Early Detection Saves Lives — The "Ugly Duckling" Sign Explained and Melanoma Survival Rates by Stage: What the Numbers Really Mean.

This content is for informational purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare provider for diagnosis and treatment.